Population heterogeneity is frequently observed among patients' treatment responses in clinical trials because of various factors such as clinical background, environmental, and genetic factors. Different subpopulations defined by those baseline factors can lead to differences in the benefit or safety profile of a therapeutic intervention. Ignoring heterogeneity between subpopulations can substantially impact on medical practice. One approach to address heterogeneity necessitates designs and analysis of clinical trials with subpopulation selection. Several types of designs have been proposed for different circumstances. In this work, we discuss a class of designs that allow selection of a predefined subgroup. Using the selection based on th...
Standard randomized trials may have lower than desired power when the treatment effect is only stron...
Randomized controlled trials (RCTs) provide reliable evidence for approval of new treatments, inform...
Recent developments in genomics and proteomics enable the discovery of biomarkers that allow identif...
The increasing awareness of treatment effect heterogeneity has motivated flexible designs of confirm...
It is a challenge to evaluate experimental treatments where it is suspected that the treatment effec...
We consider the problem of designing a randomized trial for comparing two treatments versus a common...
Standard randomized trials may have lower than desired power when the treatment effect is only stron...
Abstract: Problem statement: The common assumption in non-randomized Phase II clinical trials is a h...
Important objectives in the development of stratified medicines include the identification and confi...
Adaptive enrichment designs involve preplanned rules for modifying patient enrollment criteria based...
A critical part of clinical trials in drug development is the analysis of treatment efficacy in pati...
Precision medicine has emerged from the awareness that many human diseases are intrinsically heterog...
Precision medicine has emerged from the awareness that many human diseases are intrinsically heterog...
Recently, several study designs incorporating treatment effect assessment in biomarker‐based subpopu...
A key issue when designing clinical trials is the estimation of the number of subjects required. Ass...
Standard randomized trials may have lower than desired power when the treatment effect is only stron...
Randomized controlled trials (RCTs) provide reliable evidence for approval of new treatments, inform...
Recent developments in genomics and proteomics enable the discovery of biomarkers that allow identif...
The increasing awareness of treatment effect heterogeneity has motivated flexible designs of confirm...
It is a challenge to evaluate experimental treatments where it is suspected that the treatment effec...
We consider the problem of designing a randomized trial for comparing two treatments versus a common...
Standard randomized trials may have lower than desired power when the treatment effect is only stron...
Abstract: Problem statement: The common assumption in non-randomized Phase II clinical trials is a h...
Important objectives in the development of stratified medicines include the identification and confi...
Adaptive enrichment designs involve preplanned rules for modifying patient enrollment criteria based...
A critical part of clinical trials in drug development is the analysis of treatment efficacy in pati...
Precision medicine has emerged from the awareness that many human diseases are intrinsically heterog...
Precision medicine has emerged from the awareness that many human diseases are intrinsically heterog...
Recently, several study designs incorporating treatment effect assessment in biomarker‐based subpopu...
A key issue when designing clinical trials is the estimation of the number of subjects required. Ass...
Standard randomized trials may have lower than desired power when the treatment effect is only stron...
Randomized controlled trials (RCTs) provide reliable evidence for approval of new treatments, inform...
Recent developments in genomics and proteomics enable the discovery of biomarkers that allow identif...